Research location
Teaneck
New Jersey, United States
Advertisement
Research activity in Teaneck
New Jersey, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 154 trials and 155 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Teaneck
154 linked trials · page 1 of 4Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisNCT07325292 · 2026-01-14 · 1 site observation
RECRUITING
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.NCT06846281 · 2025-06-23 · 1 site observation
RECRUITING
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · 2025-05-22 · 1 site observation
RECRUITING
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisNCT06408259 · 2025-04-08 · 1 site observation
RECRUITING
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsNCT06418204 · 2025-01-30 · 1 site observation
RECRUITING
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT06568939 · 2025-01-20 · 1 site observation
RECRUITING
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT06667076 · 2024-12-16 · 1 site observation
RECRUITING
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)NCT06433752 · 2024-07-22 · 1 site observation
RECRUITING
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular EventsNCT06112418 · 2024-03-06 · 1 site observation
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation
RECRUITING
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)NCT04852887 · 2021-06-23 · 1 site observation
RECRUITING
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596 · 2020-12-02 · 1 site observation
RECRUITING
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 1 site observation
RECRUITING
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerNCT03678025 · 2018-09-24 · 1 site observation
RECRUITING
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityNCT03418961 · 2017-11-01 · 1 site observation
RECRUITING
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation
SUSPENDED
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)NCT06564311 · 2024-08-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic RetinopathyNCT06321302 · 2024-05-15 · 1 site observation
ACTIVE_NOT_RECRUITING
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE TrialNCT06216574 · 2024-03-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisNCT06141486 · 2023-12-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Observational Study of Persistence on Bafiertam Treatment in Routine Clinical PracticeNCT05978531 · 2023-08-17 · 1 site observation
TERMINATED
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)NCT05798520 · 2023-07-25 · 1 site observation
COMPLETED
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN StudyNCT05568472 · 2023-03-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYXNCT05467176 · 2022-10-04 · 1 site observation
COMPLETED
A Study of Ponsegromab in People With Heart FailureNCT05492500 · 2022-09-26 · 1 site observation
TERMINATED
Nesvategrast (OTT166) in Diabetic Retinopathy (DR)NCT05409235 · 2022-07-29 · 1 site observation
COMPLETED
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple SclerosisNCT05269004 · 2022-05-03 · 1 site observation
ACTIVE_NOT_RECRUITING
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic RetinopathyNCT05296447 · 2022-04-04 · 1 site observation
ENROLLING_BY_INVITATION
Bacteriophage Therapy in Patients With Diabetic Foot OsteomyelitisNCT05177107 · 2021-11-24 · 1 site observation
TERMINATED
Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying TherapyNCT05028634 · 2021-11-11 · 1 site observation
COMPLETED
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a CatNCT04981717 · 2021-07-30 · 1 site observation
TERMINATED
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)NCT04586010 · 2021-03-17 · 1 site observation
ACTIVE_NOT_RECRUITING
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationNCT04685135 · 2021-02-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal TherapyNCT04379570 · 2021-02-15 · 1 site observation
ACTIVE_NOT_RECRUITING
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)NCT04567550 · 2020-11-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple SclerosisNCT04544449 · 2020-10-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)NCT04611152 · 2020-09-30 · 1 site observation
TERMINATED
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)NCT04411641 · 2020-09-24 · 1 site observation
COMPLETED
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator ArmNCT04503551 · 2020-08-10 · 1 site observation
COMPLETED
Study of a High-Dose Aflibercept in Participants With Diabetic Eye DiseaseNCT04429503 · 2020-06-29 · 1 site observation
COMPLETED
NCI COVID-19 in Cancer Patients, NCCAPS StudyNCT04387656 · 2020-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyNCT04266249 · 2020-03-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)NCT04140305 · 2020-01-16 · 1 site observation
TERMINATED
An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisNCT04130997 · 2019-11-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of RecurringNCT04037254 · 2019-10-08 · 1 site observation
COMPLETED
Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast CancerNCT04001829 · 2019-08-09 · 1 site observation
ACTIVE_NOT_RECRUITING
Effect of Treatment on Work Experience in Patients With Stage I-III Prostate CancerNCT03963739 · 2019-07-19 · 1 site observation
COMPLETED
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaNCT03917472 · 2019-07-17 · 1 site observation
COMPLETED
Effects of a Weight Based Training Program on MS PatientsNCT04002492 · 2019-07-01 · 1 site observation
UNKNOWN
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.